Prelude Therapeutics ( (PRLD) ) just unveiled an update.
Prelude Therapeutics reported its financial results for 2024 and provided updates on its clinical development pipeline. The company highlighted the progress of its SMARCA2 degrader programs, including PRT3789, which has shown promising results in treating SMARCA4-deficient cancers. Prelude’s financial position remains strong, with a cash runway extending into the second quarter of 2026. The company continues to focus on advancing its precision oncology medicines and expects to share further data in 2025.
More about Prelude Therapeutics
Prelude Therapeutics is a clinical-stage precision oncology company focused on developing innovative therapies for cancer patients, particularly those with SMARCA4-mutated cancers. The company is advancing its SMARCA2 degraders and other targeted therapies to address significant unmet medical needs in oncology.
YTD Price Performance: -41.12%
Average Trading Volume: 395,548
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $40.51M
See more insights into PRLD stock on TipRanks’ Stock Analysis page.